{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EBV",
    "query": {
      "intervention": "EBV"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 167,
    "total_pages": 17,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=EBV&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-12T11:33:37.952Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00992732",
      "title": "Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoid Malignancies",
        "Lymphoproliferative Disorders"
      ],
      "interventions": [
        {
          "name": "HQK-1004",
          "type": "DRUG"
        },
        {
          "name": "Valganciclovir (may substitute with ganciclovir)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HemaQuest Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2010-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-08-01",
      "last_synced_at": "2026-09-12T11:33:37.952Z",
      "location_count": 8,
      "location_summary": "Palo Alto, California • San Francisco, California • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00992732"
    },
    {
      "nct_id": "NCT04040244",
      "title": "Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pneumonitis",
        "Nonsmall Cell Lung Cancer Stage III"
      ],
      "interventions": [
        {
          "name": "Exhaled Breath Collection",
          "type": "OTHER"
        },
        {
          "name": "Blood sample",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2019-12-09",
      "completion_date": "2022-03-10",
      "has_results": true,
      "last_update_posted_date": "2023-10-11",
      "last_synced_at": "2026-09-12T11:33:37.952Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04040244"
    },
    {
      "nct_id": "NCT01329185",
      "title": "Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "EBV Viremia",
        "CMV Viremia"
      ],
      "interventions": [
        {
          "name": "Valganciclovir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Months and older"
      },
      "enrollment_count": 17,
      "start_date": "2011-06",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2019-11-01",
      "last_synced_at": "2026-09-12T11:33:37.952Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01329185"
    },
    {
      "nct_id": "NCT02229981",
      "title": "Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large B Cell Lymphoma",
        "Kaposi Sarcoma"
      ],
      "interventions": [
        {
          "name": "ABC294640",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "RedHill Biopharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2014-07",
      "completion_date": "2019-12",
      "has_results": false,
      "last_update_posted_date": "2017-12-07",
      "last_synced_at": "2026-09-12T11:33:37.952Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02229981"
    },
    {
      "nct_id": "NCT06412497",
      "title": "MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Severe Aplastic Anemia",
        "Acquired Amegakaryocytic Thrombocytopenia",
        "Acquired Pure Red Cell Aplasia",
        "Paroxysmal Nocturnal Hemoglobinuria"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Rabbit ATG",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Cell Infusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Post-Transplant G-CSF",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "0 Years to 75 Years"
      },
      "enrollment_count": 60,
      "start_date": "2024-06-05",
      "completion_date": "2036-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-09-12T11:33:37.952Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06412497"
    },
    {
      "nct_id": "NCT05957913",
      "title": "Effects of Antiviral Therapies on Epstein-Barr Virus Replication",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Truvada (tenofovir/emtricitabine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2023-06-05",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-09-12T11:33:37.952Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05957913"
    },
    {
      "nct_id": "NCT00093704",
      "title": "Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Lymphoproliferative Disorder"
      ],
      "interventions": [
        {
          "name": "bortezomib + ganciclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2005-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-07-31",
      "last_synced_at": "2026-09-12T11:33:37.952Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00093704"
    },
    {
      "nct_id": "NCT02422875",
      "title": "Comparative Autoantibody and Immunologic Cell Marker Study",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Autoimmune Diseases",
        "Lupus Erythematosus, Systemic",
        "Communicable Diseases"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2500,
      "start_date": "2012-08",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2025-09-30",
      "last_synced_at": "2026-09-12T11:33:37.952Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02422875"
    },
    {
      "nct_id": "NCT02510417",
      "title": "Allogeneic Virus-specific T Cell Lines (VSTs)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Viral Infections After HSCT"
      ],
      "interventions": [
        {
          "name": "VSTs",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Catherine Bollard",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Weeks",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "4 Weeks to 45 Years"
      },
      "enrollment_count": 31,
      "start_date": "2014-10-28",
      "completion_date": "2018-01-03",
      "has_results": false,
      "last_update_posted_date": "2025-07-02",
      "last_synced_at": "2026-09-12T11:33:37.952Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02510417"
    },
    {
      "nct_id": "NCT00215033",
      "title": "Relationship Between EBV and PTLD",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pediatric Heart Transplant"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Children's Healthcare of Atlanta",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 160,
      "start_date": "2005-04",
      "completion_date": "2006-05",
      "has_results": false,
      "last_update_posted_date": "2012-03-16",
      "last_synced_at": "2026-09-12T11:33:37.952Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00215033"
    }
  ]
}